Inhibiting C5 in patients with severe COVID-19-the incorrect target? - Authors' reply.

Competing Interests: DA has received funding, paid to institution, from Alexion, AstraZeneca Rare Disease and is co-inventor on a patent pending (WO2021211940A1). SJP has received funding, paid to institution, from grants; contracts; consulting fees; and honoraria and travel expenses for lectures, advisory boards, and conference attendance from Alexion, AstraZeneca Rare Disease. He receives royalties from a patent (9,891,219B2). DD is an employee of Alexion, AstraZeneca Rare Disease, owns stock in AstraZeneca, and is a co-inventor on a patent pending (WO2021211940A1). AK has received funding, paid to institution, from Alexion, AstraZeneca Rare Disease; consulting fees from Regeneron, Samsung, Silence Therapeutics, and Novo Nordisk; and honoraria and support for attending meetings and travel from Alexion, AstraZeneca Rare Disease, Amgen, Sobi, Celgene, Bristol Myers Squibb, Biocryst, Pfizer, Roche, Novartis, and Janssen.